PRAGUE, Jan. 9, 2023 /PRNewswire/ -- Zentiva is pleased to announce that we have extended our strategic partnership with Adalvo, signing a licensing deal for three molecules, within Europe.
MSIDA, Malta--(BUSINESS WIRE)--The global pharmaceutical company Adalvo today announced the acquisition of its first branded product, Onsolis® after concluding a deal with a reputable US based specialty pharmaceutical Company, that originally owned the product.
Under the US$475 million (THB16.46 billion) acquisition deal, Innobic became the largest shareholder of Lotus Pharmaceutical with a 37 per cent stake, and of Adalvo with a 60 per cent stake. The acquisition aims to increase the strength of both Lotus Pharmaceutical and Adalvo as world leaders in pharmaceutical and patent trading industries, as well as increase Thailand’s accessibility to drugs of international standard.
MSIDA, Malta--(BUSINESS WIRE)--Adalvo, the leading global B2B pharmaceutical company, is thrilled to announce the recent establishment of a new entity ArphioTM (www.arphio.com), a venture initiated in close collaboration with SK Pharma.
Adalvo recently announced the successful closure on their DCP procedure (decentralized procedure for the European Union) for Icatibant development, a complex injectable peptide product. Icatibant, a selective and competitive bradykinin B2 receptor antagonist, is used to treat acute attacks of hereditary angioedema (HAE), a serious orphan disease. Icatibant is truly a landmark product and this DCP registration procedure was submitted within almost all the EU region. This product is an equivalent and more affordable version of Firazyr, providing more access to patients worldwide. Providing complex peptide synthesis expertise, AmbioPharm was a strategic partner and close collaborator in the development of this product.
JSC Olainfarm & Adalvo to launch a new urology product in 17 countries in 2022-2023
Adalvo today announced that it has entered into a partnership with AmbioPharm, a US-based pharmaceutical company, for an exclusive collaboration on the co-development and licensing for the commercialization of several complex pharmaceutical products in key global markets. The strategic partnership further enhances Adalvo’s product offering for global commercial partners and brings together complementary capabilities with AmbioPharm.